Karnezis, Tom T <br/><br/>
Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.  [electronic resource] 

 -  The Laryngoscope  Mar 2012 
 - 495-7 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1531-4995 
<br/><br/><label>Standard No.: </label>10.1002/lary.22501  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intranasal<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Bevacizumab<br/>Dose-Response Relationship, Drug<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections<br/>Male<br/>Middle Aged<br/>Nasal Mucosa<br/>Prospective Studies<br/>Severity of Illness Index<br/>Telangiectasia, Hereditary Hemorrhagic--diagnosis<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A